We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · August 05, 2020

Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH

Journal of Hepatology

 

Additional Info

Journal of Hepatology
Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results From Randomized Phase III STELLAR Trials
J. Hepatol. 2020 Jul 01;73(1)26-39, SA Harrison, VW Wong, T Okanoue, N Bzowej, R Vuppalanchi, Z Younes, A Kohli, S Sarin, SH Caldwell, N Alkhouri, ML Shiffman, M Camargo, G Li, K Kersey, C Jia, Y Zhu, CS Djedjos, GM Subramanian, RP Myers, N Gunn, A Sheikh, QM Anstee, M Romero-Gomez, M Trauner, Z Goodman, EJ Lawitz, Z Younossi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading